BANK VONTOBEL/CALL/BIOGEN IDEC/340/0.1/17.01.25

BANK VONTOBEL/CALL/BIOGEN IDEC/340/0.1/17.01.25 Stock

DE000VM9C0Q0

Real-time Boerse Frankfurt Warrants 08:03:52 2024-06-14 am EDT
0.26 ^EUR	-10.34%

Current month	+28.89%
1 month	+20.83%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BIOGEN INC.

Chart BANK VONTOBEL/CALL/BIOGEN IDEC/340/0.1/17.01.25

Latest news about BIOGEN INC.

Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB	05:46am	PR
REGENXBIO Inc. Announces Chief Executive Officer Changes	Jun. 13	CI
Biogen executive plays down looming competition for its Alzheimer's drug	Jun. 12	RE
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit	Jun. 12	PR

More news

Quotes 5-day view

Date	Price	Change
24-06-14	0.26	-10.34%
24-06-13	0.29	+20.83%
24-06-12	0.24	+9.09%
24-06-11	0.22	-4.35%
24-06-10	0.23	-4.17%

Real-time Boerse Frankfurt Warrants

Last update June 14, 2024 at 08:03 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BIOGEN INC.
Issuer	Vontobel
WKN	VM9C0Q
ISIN	DE000VM9C0Q0
Date issued	2024-01-30
Strike	340 $
Maturity	2025-01-17 (217 Days)
Parity	10 : 1
Emission price	0.66 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.26 €
Lowest since issue	0.08 €
Spread	0.09 €
Spread %	25.71%

Company Profile

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.

Sector

More about the company